Vor Biopharma (VOR) Proxy filing summary

Voting matters and shareholder proposals

• Election of two Class II director nominees, Andrew Levin and Fouad Namouni, each for a three-year term expiring at the 2029 annual meeting and until a successor is duly elected and qualified.

• Approval of the amendment and restatement of the 2021 Equity Incentive Plan is proposed.

• Ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.

Board of directors and corporate governance

• Board recommends a vote in favor of all director nominees and the listed proposals.

Audit committee and external auditor matters

• Audit committee has selected Ernst & Young LLP as the independent auditor for the upcoming fiscal year.